Monograph Details
|
|
Central Nervous System
> ADHD/narcolepsy
|
|
VYVANSE |
| Manufacturer |
|
Shire US, Inc. |
| Legal Classification |
|
CII |
| Pharmacological Class |
|
Stimulant. |
| Generic Name |
|
Lisdexamfetamine dimesylate 20mg, 30mg, 40mg, 50mg, 60mg, 70mg; caps. |
| Indications |
|
Attention deficit hyperactivity disorder. |
| Children |
|
<6yrs: not recommended. 6–12yrs: 30mg once daily in AM. May increase at 1-week intervals by 10mg or 20mg per day; max 70mg/day. May dissolve contents of capsule in water, take immediately (do not subdivide caps). |
| Adults |
|
≥18yrs: 30mg once daily in AM. May increase at 1-week intervals by 10mg or 20mg per day; max 70mg/day. May dissolve contents of capsule in water, take immediately (do not subdivide caps). |
| Contraindications |
|
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug abusers. Hypersensitivity or idiosyncrasy to sympathomimetics. Within 14 days of MAOIs. |
| Precautions |
|
Bipolar disorder. Psychoses. Tourette's syndrome. Tics. Structural cardiac abnormalities. Arrythmias. Hypertension. Heart failure. Recent MI. Discontinue if seizures occur. Drug abusers. Impaired renal, hepatic, or thyroid function. Reevaluate periodically. Monitor growth, BP, heart rate, worsening aggressive behavior or hostility. Write Rx for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Hypertensive crisis with MAOIs, furazolidone. Potentiated by tricyclics, propoxyphene, urinary alkalinizing agents. Potentiates meperidine, norepinephrine, phenobarbital, phenytoin, tricyclics. Antagonized by urinary acidifiers, methenamine therapy, psychotropics (eg, haloperidol, chlorpromazine), lithium. Antagonizes adrenergic blockers, antihistamines, veratrum alkaloids, ethosuximide, antihypertensives. Monitor phenytoin, ethosuximide, phenobarbital. Convulsions with propoxyphene overdose. Caution with other sympathomimetics. May interfere with urinary steroid tests. |
| Adverse Reactions |
|
Decreased appetite/weight, dry mouth, irritability, jitteriness, dizziness, headache, anxiety, fatigue, insomnia, upper abdominal pain, GI upset; hypertension, blurred vision, psychosis, tics, rash (may be serious). |
| How Supplied |
|
Caps—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
